Lancet Sub-Journal: Here comes the evidence-absolutely necessary!

In 2018, "The Lancet " released the "Global Burden of Diseases, Injuries, and Risk Factors Study 2016" (Global Burden of Diseases, Injuries, and Risk Factors Study 2016, hereinafter referred to as GBD).

Looking at the Lancet as a whole, the medical capabilities of countries around the world are roughly related to the level of national economic development.

It is undeniable that in the treatment of tumors, surgery undoubtedly provides patients with the best treatment opportunities, especially in the early stages of the disease.

Therefore, in addition to the increase in treatment methods, more and more people are suggesting the use of advanced imaging methods to improve global cancer care.

Data show that 2015 global total of 1500-200 Wan was diagnosed with cancer, of which 80% require surgery.

In 2015 , a total of 15-2 million were diagnosed with cancer worldwide , 80% of which required surgery.

So, what is the result of expanding the combination of imaging and treatment modalities on cancer survival and lifelong health and economic benefits globally and by national income group? In particular, is it necessary to expand treatment and examination for patients with LMICs? To this end, experts from Harvard University Medical School and the international EPC organization conducted a comprehensive assessment of the issue.

Using the previously developed global cancer survival model, researchers estimated that the 11 most common types of cancers (esophagus, stomach, colon, rectum, anus, liver, pancreas, lung, breast, cervix and uterus) were diagnosed in 200 countries and regions.

diagnosis

Researchers mainly assessed current cancer treatment methods (chemotherapy, surgery, radiotherapy, and targeted therapy), imaging methods (ultrasound, X-ray, CT, MRI, PET, PET-CT) and medical quality, and expanded inspections and treatments.

The results show that for the 11 cancers studied, if the scale is not expanded (that is, based on the current quality of treatment, imaging and care), between 2020 and 2030, there will be 760,000 cancer deaths (95 %UI 73-9-78-6), of which more than 70% of deaths occur in low- and middle-income countries.

If the scale is not scaled up (that is, based on the current quality of treatment, imaging and care), between 2020 and 2030, there will be 760,000 cancer deaths (95% UI 73-9-78-6) in patients diagnosed globally.

The overall improvement in the quality of treatment, imaging and care can prevent 12.

Researchers estimate that on a global scale, a full scale expansion will cost an additional US$232-9 billion between 2020 and 2030, representing an increase of 6.

Globally, a full scale expansion will cost an additional US$232-9 billion between 2020 and 2030, representing a 6.

The study shows that investing in cancer treatment, imaging, and quality of care at the same time can produce huge health and economic benefits, especially in low- and middle-income countries.

references:

Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis.

Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis.
Leave a message here